Crenolanib for treating FLT3 mutated proliferative disorders
The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
1. A method for treating a FLT3 mutated hematologic malignancy in a patient that comprises administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the FLT3 mutated hematologic malignancy is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, or idiopathic hypereosinophilic syndrome (HES).
2. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof are from about 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day.
3. The method of claim 1 , wherein the mutated FLT3 is defined further as a constitutively active FLT3 mutant.
4. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered orally, intravenously, or intraperitoneally.
5. The method according to claim 1 , wherein the crenolanib is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulphonate and crenolanib succinate.
6. The method of claim 1 , wherein the FLT3 is at least one of FLT3-ITD or FLT-TKD.
7. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is at least one of: (1) administered at least one of continuously, intermittently, systemically, or locally, (2) administered up to three times or more a day for as long as the subject is in need of treatment for the FLT3 mutated hematologic malignancy; (3) sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed hematologic malignancy patient, to maintain remission, or a relapsed/refractory hematologic malignancy patient; (4) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy patient, to maintain remission, or a relapsed/refractory hematologic malignancy patient; or (5) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy pediatric patient, to maintain remission, or a relapsed/refractory FLT3 mutated hematologic malignancy pediatric patient.
8. The method of claim 1 , wherein the patient is relapsed/refractory to other FLT3 tyrosine kinase inhibitors or another chemotherapy.
9. A method for treating a patient suffering from a FLT3 mutated hematologic malignancy comprising:
identifying the patient in need of therapy for the FLT3 mutated hematologic malignancy; and
administering to the patient in need of such treatment a therapeutically effective amount of crenolanib or a salt thereof, wherein the FLT3 mutated hematologic malignancy is characterized by deregulated FLT3 receptor tyrosine kinase activity, wherein the FLT3 mutated hematologic malignancy is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES).
10. The method of claim 9 , wherein the crenolanib or a salt thereof is administered orally, intravenously, or intraperitoneally.
11. The method of claim 9 , wherein the Crenolanib or a salt thereof is at least one of crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib touluenesulphonate and crenolanib succinate.
12. The method of claim 9 , wherein the FLT3 is at least one of FLT3-ITD or FLT3-TKD.
13. The method of claim 9 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is at least one of: (1) administered at least one of continuously, intermittently, systemically, or locally, (2) administered up to three times or more a day for as long as the subject is in need of treatment for the FLT3 mutated hematologic malignancy; (3) sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy patient, to maintain remission, or a relapsed/refractory FLT3 mutated hematologic malignancy patient; (4) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy patient, to maintain remission, or a relapsed/refractory hematologic malignancy patient; or (5) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy pediatric patient, to maintain remission, or a relapsed/refractory hematologic malignancy pediatric patient.
14. The method of claim 9 , wherein the patient is refractory to at least one other tyrosine kinase inhibitor or another chemotherapy.
15. A method for treating a patient suffering from leukemia comprising:
obtaining a sample from the patient suspected of having leukemia;
determining from the patient sample that the patient has a deregulated FLT3 receptor tyrosine kinase; and
administering to the patient in need of such treatment a therapeutically effective amount of crenolanib or a salt thereof, wherein the leukemia is characterized by deregulated FLT3 receptor tyrosine kinase activity.
16. The method of claim 15 , wherein the leukemia is selected from Hodgkin's disease, and myeloma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, AML, with trilineage myelodysplasia (AMLITMDS), mixed lineage leukemia (MLL), myelodysplastic syndromes (MDSs), myeloproliferative disorders (MPD), and multiple myeloma (MM).
17. A method for specifically inhibiting a deregulated receptor tyrosine kinase comprising:
obtaining a patient sample;
determining which receptor tyrosine kinases are deregulated; and
administering to a mammal in need of such treatment a therapeutically effective amount of crenolanib or a salt thereof, wherein the deregulated receptor tyrosine kinase is a FLT3 receptor tyrosine kinase sufficient to treat a FLT3 mutated hematologic malignancy, wherein the FLT3 mutated hematologic malignancy is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES).
18. The method of claim 17 , wherein the therapeutically effective amount of crenolanib or a salt thereof is provided in an amount that decreases patient circulating peripheral blood blast count.
19. The method of claim 17 , wherein the therapeutically effective amount of crenolanib or a salt thereof is provided in an amount that decreases a patient bone marrow blast count.
20. The method of claim 17 , wherein the therapeutically effective amount of crenolanib or a salt thereof is also provided prophylactically at effective amounts are from about 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day.
21. The method of claim 17 , wherein the deregulated FLT3 is defined further as a mutated FLT3 is constitutively active.
22. The method of claim 17 , wherein therapeutically effective amount of crenolanib or a salt thereof is administered orally, intravenously, or intraperitoneally.
23. The method of claim 17 , wherein the crenolanib is at least one of crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib touluenesulphonate and crenolanib succinate.
24. The method of claim 17 , wherein the FLT3 is at least one of FLT3-ITD or FLT3-TKD.
25. The method of claim 17 , wherein the patient is provided treatment, and the method further comprises the steps of obtaining one or more patient samples to determine the effect of the treatment, and continuing treatment until the FLT3 mutated hematologic malignancy is reduced or eliminated.
26. The method of claim 17 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is at least one of: (1) administered at least one of continuously, intermittently, systemically, or locally, (2) administered up to three times or more a day for as long as the subject is in need of treatment for the FLT3 mutated hematologic malignancy; (3) sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy patient, to maintain remission, or a relapsed/refractory FLT3 mutated hematologic malignancy patient; (4) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy patient, to maintain remission, or a relapsed/refractory FLT3 mutated hematologic malignancy patient; or (5) as a single agent or in combination with another pharmaceutical agent in a newly diagnosed FLT3 mutated hematologic malignancy pediatric patient, to maintain remission, or a relapsed/refractory FLT3 mutated hematologic malignancy pediatric patient.
27. The method of claim 17 , wherein the patient is relapsed/refractory to a prior tyrosine kinase inhibitor or another chemotherapy.
28. A method for treating a patient with a hematologic malignancy comprising:
obtaining a sample from the patient;
determining if the patient that has become resistant to prior tyrosine kinase inhibitors or chemotherapy and has a FLT3 mutated hematologic malignancy, wherein the FLT3 mutated hematologic malignancy is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, or idiopathic hypereosinophilic syndrome (HES); and
administering a therapeutically effective amount of crenolanib or a salt thereof to overcome the resistance to the prior protein tyrosine kinase inhibitors.